Investment Banker Dick Huebner on How to Uncover Micro-Cap Biotechs that Deliver on Promises

November 21, 2014 (Investorideas.com Newswire) Micro-cap stocks suffer from all sorts of ills. They are often illiquid, and companies can be unable to raise new funds under reasonable terms, if at all.

Breaking Pharma Stock News: Actavis (ACT) to Acquire Allergan (AGN) to Create Top 10 Global Growth Pharmaceutical Company with $23 Billion in Revenue

DUBLIN and IRVINE, Calif. - November 17, 2014 (Investorideas.com Newswire) Actavis plc (ACT) and Allergan, Inc. (AGN) today announced that they have entered into a definitive agreement under which Actavis will acquire Allergan for a combination of $129.22 in cash and 0.3683 Actavis shares for each share of Allergan common stock.

R. Lee Buckler: How RepliCel Is Harnessing the Awesome Power of Cell Therapy

November 7, 2014 (Investorideas.com Newswire) Regenerative medicine and cell therapies hold possibilities for achieving near miracles in a multitude of indications, from life-saving treatments to aesthetic applications.

A Tour of Australian Biotechs with Morgans' Scott Power

October 2, 2014 (Investorideas.com Newswire) Australia is a powerhouse for medical science innovations, and nobody understands that better than Scott Power of Morgans Financial Ltd.

Wedbush Securities' Liana Moussatos on the Art and Science of Picking Biotechs with Upside

August 21, 2014 (Investorideas.com Newswire) Liana Moussatos of Wedbush Securities doesn't wait for the catalyst to strike. She, like other successful investors, picks her targets and takes profits earlier, while less sophisticated investors wait for the press releases.

Biotech Stock Directory Update

New York, NY - Point Roberts, WA - August 14, 2014 (Investorideas.com Newswire) Investorideas.com staff: Investorideas.com, a global news source covering leading sectors issues the updated biotech stock directory for August.

Pharma Stock CASI Pharmaceuticals (CASI) Receives U.S. Orphan Drug Designation For The Use Of ENMD-2076 To Treat Hepatocellular Carcinoma

ROCKVILLE, MD - July 9, 2014 (Investorideas.com Newswire) CASI Pharmaceuticals, Inc. (CASI), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other diseases, announced today that its orally-active, Aurora A/angiogenic kinase inhibitor, ENMD-2076, has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of hepatocellular carcinoma (HCC).

Fire Up the Immuno-Oncology Powerhouses: John McCamant

June 19, 2014 (Investorideas.com Newswire) Forecasting when we'll have a cure for cancer remains beyond the predictive powers of researchers and investors.

Medical Technology News: Medical Technology The Role of Aethlon Medical (OTCQB: AEMD) in the Emerging Immuno-Oncology Market; Q&A with Aethlon Chairman and CEO, Jim Joyce

Point Roberts, WA, NEW YORK, NY - June 10, 2014 (Investorideas.com newswire) Investorideas.com, a global news source covering leading sectors including biotech and medical technology issues a Q&A interview with Mr. James A. Joyce ,Chairman and CEO of Aethlon Medical, Inc. (OTCBB:AEMD).

ASCO Abuzz About Immunotherapies: A Preview of the Latest in Cancer Therapy from Stephen Dunn

May 29, 2014 (Investorideas.com Newswire) Working in what is arguably the hottest sector in the drug development industry, biotech researchers continue to ferret out cancer's secrets.

Turn Solid Gold into Biotech Gold with James West

May 29, 2014 (Investorideas.com Newswire) The globe-trotting editor and publisher of The Midas Letter has decided to give his metal investments a breather, looking for new prospects in the life sciences space.

Harnessing the Power of Nature's Perfect Cells: Robert J. Hariri

May 23, 2014 (Investorideas.com Newswire) Neurosurgeon and serial entrepreneur Robert J. Hariri, founder, chairman and chief science officer at Celgene Cellular Therapeutics, describes how his businesses address some of the great unmet needs in medicine in this interview with The Life Sciences Report.

Live Longer, Get Richer with Patrick Cox

May 8, 2014 (www.investorideas.com newswire) It's what every biotech investor dreams of: Transformational advances in healthcare technologies that allow us to live for centuries and accumulate wealth exponentially.

X-Ray Vision or Due Diligence? How SeeThruEquity Analysts Find Hidden Small-Cap Biotech Plays

May 2, 2014 (Investorideas.com Newswire) SeeThruEquity stays an arm's length away from the small biotech firms it analyzes for investors, but gets intimate enough to discover firms that hold promise.

New Melanoma Therapies Are Ready for Primetime: Sanjiv Agarwala

April 30, 2014 (Investorideas.com Newswire) Melanoma confronts patients and their physicians with unique barriers to treatment and successful outcomes.

Do the Math: Ram Selvaraju on the Appeal of Biotechs in Orphan Diseases

April 22, 2014 (Investorideas.com Newswire) To cast a spotlight on disruptive biotechnology stocks, Raghuram "Ram" Selvaraju of Aegis Capital Corp. taps his experience as a molecular biologist, preclinical investigator and sellside analyst.

TSX Biotech Stocks to Watch; Innovative Ovarian Cancer Treatments

New York, NY - Point Roberts, WA - March 26, 2014 (Investorideas.com Newswire) Investorideas.com, a global news source for leading sectors including biotech and pharma issues a sector snapshot of TSX biotech stocks targeting ovarian cancer as part of their product pipeline.

Biopharma IPO alert: Versartis, Inc., (Nasdaq:VSAR) Soars

New York, NY - Point Roberts, WA - March 21, 2014 (Investorideas.com Newswire) Investorideas.com, a global financial and business news source covering leading sectors including biotech issues an IPO alert for Versartis, Inc., (Nasdaq:VSAR) an endocrine-focused biopharmaceutical company.

IPO Alert: Akebia Therapeutics, Inc. (AKBA) Surges in NASDAQ Market Debut

New York, NY - Point Roberts, WA - March 20, 2014 (Investorideas.com Newswire) Investorideas.com, a global financial and business news source covering leading sectors including biotech, issues an IPO alert on Akebia Therapeutics, Inc. (AKBA).

Promising Biotechs Target New Ways to Kill Bad Bugs: Venture Capitalist Dennis Purcell

March 18, 2014 (Investorideas.com Newswire) Dennis Purcell, senior managing partner of Aisling Capital, has seen the biotechnology industry morph from exciting science project to a full-blown, multibillion-dollar industry producing blockbuster products that routinely save lives.

Read More

Subscribe to InvestorIdeas-Biotech News

George Zavoico Lists 10 Biotech Stocks Poised to Run - March 7, 2013

March 7, 2013 (Investorideas.com Newswire) For the first time in ages, conditions for biotech investment are just right.

Oculus Innovative Sciences, Inc. (NasdaqCM:OCLS) - is a commercial healthcare company that designs, produces and markets innovative, safe and effective healthcare products. Oculus is pioneering innovative solutions in multiple markets including dermatology, oral care, surgical, wound care, animal healthcare and others, and has commercialized products in the United States , Europe, India , China , Mexico , and select Middle East countries. The company's headquarters are in Petaluma , California , with manufacturing operations in the United States and Latin America. www.oculusis.com.

Our biotech stocks directory includes Stem Cell Stocks, Medical Stocks, Life Sciences, Therapeutics and Pharma Stocks . Our Directory includes publicly traded biotech stocks on the TSX, TSX Venture, OTC, NASDAQ, AMEX, NYSE, ASX, AIM and other leading Stock Exchanges.

Preview

3SBio Inc. (NasdaqGS:SSRX) is a leading, fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China. Its focus is on addressing large markets with significant unmet medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious diseases. With headquarters and GMP certified manufacturing facilities in Shenyang, PRC, 3SBio employs over 500 people.

Aastrom Biosciences, Inc. (NasdaqCM: ASTM) is developing expanded autologous cellular therapies for the treatment of severe cardiovascular diseases. The company's proprietary cell manufacturing technology enables the production of cellular therapies expanded from a patient's own bone marrow and delivered directly to damaged tissues. Aastrom has advanced its cell therapies into late-stage clinical development, including a planned Phase 3 clinical program for the treatment of patients with critical limb ischemia and two ongoing Phase 2 clinical trials in patients with dilated cardiomyopathy.

ABBOTT LABORATORIES (NYSE: ABT) is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics.  The company employs nearly 90,000 people and markets its products in more than 130 countries.

Ablynx (Brussels: ABLX.BR) is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life-threatening human diseases, including inflammation, thrombosis, oncology and pulmonary disease. Today, the Company has over 25 projects in the pipeline and there are seven Nanobodies in clinical development. Ablynx has ongoing research collaborations and significant partnerships with major pharmaceutical companies, including Boehringer Ingelheim, Merck Serono, Novartis and Pfizer. The Company is headquartered in Ghent, Belgium and currently employs over 280 people.

See the full biotech stocks directory and login as a member or access as a PDF

• AMEX Biotechnology Index (BTK) The Biotechnology Index is designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. - Click here for current quotes of index components
• Amex Pharmaceutical Index (AMEX: ^DRG) Components - click here
• CBN Stock Index: Canadian Biotech News tracks the stock prices of all publicly listed companies involved in the biotechnology industry in Canada. Our Index however is composed of therapeutic and diagnostics companies whose stock price in the quarter ranges above $1.00. The CBN Index is an average of these prices added to a starting baseline of 100.
• NASDAQ Biotechnology Index includes securities of Nasdaq-listed companies classified according to the Industry Classification Benchmark as either Biotechnology or Pharmaceuticals which also meet other eligibility criteria. The NASDAQ Biotechnology Index is calculated under a modified capitalization-weighted methodology. - click here
• S&P Sector Indices Brochure
• First Trust NYSE Arca Biotech Index (FBT)
• Market Vectors Biotech ETF (BBH) -NYSE MKT- Market Vectors exchange-traded products have been offered since 2006 and span many asset classes, including equities, fixed income (municipal and international bonds) and currency markets. The Market Vectors family currently totals $25.1 billion in assets under management, making it the fifth largest ETP family in the U.S. and eighth largest worldwide
• ProShares UltraShort Nasdaq Biotech (BIS)

Biotech stocks News; A Tale of Two Biotech Companies: Q&A With Roche (SIX: RO, ROG; OTCQX: RHHBY) and Sunshine Biopharma (OTCBB: SBFM) Discussing Lead Cancer Products - July 16, 2012

Biotech Investor Q&A with CFO of Sunshine Biopharma (OTCBB: SBFM) Discussing its Lead Compound - Adva-27a for Aggressive Forms of Cancer - July 2, 2012

Q&A Interview with CEO of BioSante Pharmaceuticals (NasdaqGM: BPAX) Following News of Positive LibiGel® Safety Data Review in Phase III Program - October 24, 2011

Biotech Q&A; BioSante Announces Completion of Enrollment in LibiGel Safety Study - June 7, 2011

Q&A with Aethlon Medical (OTCBB: AEMD) CEO, Jim Joyce; The Potential for the Hemopurifier® Medical Device in Cancer Immunotherapy - June 28, 2011

• The Best-Performing Biotechnology Stocks Of 2014 - Forbes (Fri, 02 Jan 2015 15:37:14 GMT)  

  The Best-Performing Biotechnology Stocks Of 2014 Forbes It was an amazing year for biotech investors, although not quite as eye-popping as 2013, when four biotechnology stocks quintupled in value. The Amex Biotechnology Index rose 48%, 4% less than in 2013. The biggest upside came from an unexpected ...

• The four biotech stocks to watch this year - Sydney Morning Herald (Thu, 01 Jan 2015 00:09:22 GMT)  

  Sydney Morning Herald

  The four biotech stocks to watch this year Sydney Morning Herald After a disappointing year for local biotechnology stocks, in which a number of high profile companies faltered on the back of poor clinical results or internal blunders, investors are scouring the sector for the next big thing in 2015. The past year ...

• Hot Biotech Stocks: Isis, Kite Jump On Big Deals ISIS KITE - Investor's Business Daily (Mon, 05 Jan 2015 23:25:13 GMT)  

  Hot Biotech Stocks: Isis, Kite Jump On Big Deals ISIS KITE Investor's Business Daily Biotech Isis Pharmaceuticals leapt 10% to a new high above 68 Monday after it signed a licensing deal with Johnson & Johnson worth up to $835 million. Johnson & Johnson's (NYSE:JNJ) Janssen Biotech arm agreed to pay $35 million upfront and up to ... and more »